Sign In
Buy NVO
$47.42
+1.52 (+3.31%)
At Close: Jun 23, 2026
First Look: McDonald's beats, Hims sued, WBD deal battle
07:39am, Thursday, 12'th Feb 2026
Stock News Futures edge up as jobs data and earnings mix: U.S. stock futures inched higher after January payrolls rose 130,000 with unemployment at 4.3%, compli
Eli Lilly vs Novo Nordisk in the Weight Loss Drug Market: Here's What Investors Need to Know.
05:10am, Thursday, 12'th Feb 2026
Eli Lilly and Novo Nordisk dominate the weight loss drug market, one that soon may approach $100 billion. One of these players has recently gained market share.
Novo Nordisk plans to launch Wegovy vials
04:24pm, Wednesday, 11'th Feb 2026
Novo Nordisk said on Wednesday it plans to launch its weight-loss pill Wegovy in vials.
Novo Nordisk CEO on Hims Suit, Wegovy Demand and Pricing
04:07pm, Wednesday, 11'th Feb 2026
Novo Nordisk says more than 246,000 people are now taking its weight-loss pill. CEO Mike Doustdar sits down with Bloomberg's Katie Greifeld to discuss GLP-1 supply, pricing and the company's lawsuit a
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
03:14pm, Wednesday, 11'th Feb 2026
Bagsværd, Denmark, 11 February 2026 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated
Novo Nordisk faces a defining year in the obesity drug market. It's off to a dramatic start
03:03pm, Wednesday, 11'th Feb 2026
Novo Nordisk CEO Mike Doustdar has a plan to steer the company through what's been described as a “show me” year. The Danish drugmaker kicked off 2026 with its explosive obesity pill launch, but
More than a third of patients on Wegovy pill are new to GLP-1 drugs, study finds
01:12pm, Wednesday, 11'th Feb 2026
Among early users of Novo Nordisk's new Wegovy weight-loss pill, 36% had no prior experience taking a GLP-1 medication, a new study from the health data firm Truveta found.
Novo Nordisk CEO sees 15 million-patient opportunity in Medicare coverage for obesity drugs
11:25am, Wednesday, 11'th Feb 2026
Novo Nordisk CEO Mike Doustdar says the company is aiming to capture around 15 million new patients when Medicare starts covering obesity treatments. Doustdar said he doesn't expect Medicare access to
Is Novo Nordisk's Turnaround Story at Risk After Weak 2026 Outlook?
10:55am, Wednesday, 11'th Feb 2026
NVO expects to face a shaky 2026 as Ozempic and Wegovy sales slow down and guidance signals decline despite a milestone oral Wegovy launch.
Healthcare Stocks Are Sinking. Here Are 2 to Buy on the Dip.
10:15am, Wednesday, 11'th Feb 2026
Eli Lilly is priced for perfection thanks to its GLP-1 drugs, while Wall Street seems to have forgotten about these two high-yield healthcare stocks.
Novo Nordisk target cut by Deutsche Bank despite long-term optimism
08:45am, Wednesday, 11'th Feb 2026
Deutsche Bank has cut its price target for Novo Nordisk (NYSE:NVO) by 16% to DKK400 following a turbulent week for the Danish pharmaceutical group, citing revenue headwinds, management uncertainty and
Novo Nordisk target cut by Deutsche Bank despite long-term optimism
08:42am, Wednesday, 11'th Feb 2026
Deutsche Bank has cut its price target for Novo Nordisk (NYSE:NVO) by 16% to DKK400 following a turbulent week for the Danish pharmaceutical group, citing...
First Look: Jobs Data Looms; WBD-NFLX Fight, Moderna Setback
07:40am, Wednesday, 11'th Feb 2026
Stock News FDA refuses to file Moderna's flu shot: Moderna (MRNA) said the FDA issued a refusal-to-file letter for its mRNA flu vaccine application, citing tria
Breakfast News: First SaaS, Now Finance Hit By AI
07:30am, Wednesday, 11'th Feb 2026
AI makes move into tax planning, Shopify and Unity report this morning, and more
GLP-1 Lawsuits Are the Black Swan Risk Investors Aren’t Watching
07:15am, Wednesday, 11'th Feb 2026
One of the biggest trends in the fight against obesity has been the explosion in popularity of GLP-1 medications. Created to treat diabetes, patients who were prescribed the popular GLP-1 drugs Ozempi
